Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC

non-small cell lung cancer, alk-positive lung cancer, alk inhibitor (alki), nsclc, anaplastic lymphoma kinase (alk) fusion oncogene nsclc, guardant360 assay, next-generation sequencing (ngs) dna sequencing test, cell-free circulating tumor dna (ctdna), plasma profiling, blood-based assay, mutational testing, 74 genetic alterations (point mutations, copy number variants, fusions, insertions, deletions)